Qelbree

Chemical Nameviloxazine
Dosage FormExtended-release capsule (oral; 100 mg, 150 mg and 200 mg)
Drug ClassInhibitors
SystemNervous
CompanySupernus Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Qelbree (viloxazine) Prescribing Information.2021Supernus Pharmaceuticals, Inc. Rockville, MD